These experimental replicon shots are primary funded by BARDA with support from the Gates Foundation, who gave Arcturus Therapeutics a $928,563 grant in October 2024 to “improve understanding of durability of protection after administration of nucleic-acid based vaccines.”
Click Here for More Information